|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 2 (January 15), 1997:
pp. 376-387
RAPID COMMUNICATION
Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RAR Under Control of Cathepsin G Regulatory Sequences
By
Jay L. Grisolano,
Robin L. Wesselschmidt,
Pier Giuseppe Pelicci, and
Timothy J. Ley
From the Departments of Internal Medicine and Genetics, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University Medical School, St Louis, MO; and the Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.
 |
ABSTRACT |
Acute promyelocytic leukemia (APML) is characterized by abnormal myeloid development, resulting an accumulation of leukemic promyelocytes that are often highly sensitive to retinoic acid. A balanced t(15; 17) (q22; q21) reciprocal chromosomal translocation is found in approximately 90% of APML patients; this translocation fuses the PML gene on chromosome 15 to the retinoic acid receptor  (RAR) gene on chromosome 17, creating two novel fusion genes, PML-RAR and RAR-PML. The PML-RAR fusion gene product, which is expressed in virtually all patients with t(15; 17), is thought to play a direct role in the pathogenesis of APML. To determine whether PML-RAR is sufficient to cause APML in an animal model, we used the promyelocyte-specific targeting sequences of the human cathepsin G (hCG) gene to direct the expression of a PML-RAR cDNA to the early myeloid cells of transgenic mice. Mice expressing the hCG-PML-RAR transgene were found to have altered myeloid development that was characterized by increased percentages of immature and mature myeloid cells in the peripheral blood, bone marrow, and spleen. In addition, approximately 30% of transgene-expressing mice eventually developed acute myeloid leukemia after a long latent period. The splenic promyelocytes of mice with both the nonleukemic and leukemic phenotypes responded to all-trans retinoic acid (ATRA) treatment, which caused apoptosis of myeloid precursors. Although low-level expression of the hCG-PML-RAR transgene is not sufficient to directly cause acute myeloid leukemia in mice, its expression alters myeloid development, resulting in an accumulation of myeloid precursors that may be susceptible to cooperative transforming events.
| |
INTRODUCTION |
ASPECIFIC t(15; 17) chromosomal translocation is detected in most cases of acute promyelocytic leukemia (APML) and is often the only cytogenetic abnormality observed.1,2 The breakpoints of this translocation have been localized to the PML gene on chromosome 15 and the RAR gene on chromosome 17.3-8 Transcripts corresponding to the reciprocal fusion genes generated by this translocation (PML-RAR and RAR-PML) have been detected in the leukemic blasts of APML patients.4,5,8-10 Expression of PML-RAR has been detected in virtually all APML patients with the t(15; 17) translocation; 70% to 80% of these patients also express RAR-PML.4,5,8-10 In addition, expression of PML-RAR has been shown to produce the phenotypic features of APML blasts in several myeloid cell lines.11,12 Thus, it has been suggested that PML-RAR may be directly involved in the pathogenesis of APML.
The RAR gene encodes a hormone-inducible nuclear receptor that has been shown to be involved in myeloid development.13-16 The PML-RAR fusion gene product retains the critical functional domains of the normal RAR protein, including the domains for DNA binding, dimerization, and retinoic acid binding.4-6,8 Therefore, it has been suggested that PML-RAR may promote leukemogenesis by interfering with normal RAR signaling pathways. In transient transfection assays, PML-RAR has been shown to interfere with the activation of retinoic acid-responsive reporter genes by RAR.5,17 This effect is presumably mediated at the level of DNA binding. PML-RAR homodimers or PML-RAR/RXR heterodimers, both of which form in vitro, may directly compete with RAR/RXR heterodimers for binding to retinoic acid response elements (RAREs); alternatively, PML-RAR may act indirectly by sequestering RXRs, thus preventing RAR/RXR heterodimer formation.18 The rearrangement of the RAR gene associated with this disease is intriguing considering that APML blasts are sensitive to all-trans retinoic acid (ATRA) in vitro and in vivo.19-23 In addition, ATRA is capable of inducing complete remissions in most APML patients with the t(15; 17).19,20,22,23 Furthermore, the PML-RAR fusion protein itself is likely to be responsible for ATRA sensitivity.11
Alternatively, PML-RAR may promote leukemogenesis by interfering with normal PML function. Although the exact cellular functions of this protein are not yet understood, PML has been characterized as a tumor suppressor; disruption of this tumor suppressor by the t(15,17) translocation may be required to produce APML.24,25 PML appears to be expressed in a variety of types,26 but expression of PML-RAR under the control of PML regulatory elements is associated only with myeloid transformation. Analysis of the predicted amino acid sequence of PML showed three N-terminal cysteine/histidine-rich regions, the first of which has high homology to the RING domain characteristic of a novel family of nuclear proteins, and a putative coiled-coil domain in the C-terminus that may mediate dimerization.3-8 In APML blasts, the normal subcellular localization of PML (in discrete nuclear structures known as PML oncogenic domains [PODs]) is disrupted by the expression of PML-RAR.27-31 In fact, a direct interaction between the fusion protein and PML has been suggested to be the cause of PML delocalization from PODs.28 Remarkably, ATRA treatment of APML blasts causes PML to be restored to its normal POD structures27-29,31; however, it is not yet clear whether disruption of PML localization from PODs is directly important for the pathogenesis of APML.
Because APML is associated with overabundant promyelocytes, a progenitor cell with a committed phenotype may be the target for transformation.32 The promyelocyte stage of development is characterized by the synthesis of the primary (azurophil) granules; the enzymes that are packaged within these granules are synthesized during this stage of development. We have shown that the gene encoding one of these enzymes, cathepsin G (CG), is expressed exclusively in promyelocytes.33,34 We further showed that all of the sequences required for the early myeloid-specific expression of the human CG (hCG) gene in transgenic mice are present within a 6-kb genomic fragment.35 Using these sequences, we wanted to determine whether targeted expression of PML-RAR in the early myeloid cells of transgenic mice would recapitulate the APML disease phenotype. In this study, we have determined that mice expressing PML-RAR have altered myeloid development; however, low levels of PML-RAR expression are not sufficient to directly cause myeloid leukemia. Acute myeloid leukemia does develop after a long latent period in many mice, suggesting that a second hit is required for the development of APML.
| |
MATERIALS AND METHODS |
Construction of the transgene.
The neo cassette was removed from the -76 hCG-neo plasmid36 by digestion with HindIII. A synthetic polylinker (60 bp in length) designed with HindIII ends was then subcloned downstream from the CG promoter. The 3.5-kb hCG gene was generated by polymerase chain reaction (PCR) with 5' Sph I and 3' BamHI ends for directional cloning into the polylinker. Approximately 1 kb of sequence from each end of the PCR-generated hCG gene was verified using the Sequenase kit (US Biochemical, Cleveland, OH). The 2.4-kb 5' flank of the hCG gene was subcloned into the EcoRI site at -76 of the hCG promoter. The PML-RAR cDNA was then subcloned as a blunt-ended fragment into the Not I site of the polylinker. The completed 9-kb transgene was released from pUC 9 sequences by codigestion with Sal I and BamHI. Transgenic mice were then generated using this purified fragment as previously described.35
RNA analysis by reverse transcriptase-PCR (RT-PCR).
Total cellular RNA was purified from bone marrow cells isolated from the femurs of mice as described.37 One microgram of RNA was then analyzed by RT-PCR (Perkin-Elmer, Norwalk, CT) according to the manufacturer's instructions. One-fourth of the total reaction volume was then subjected to agarose gel electrophoresis. The fractionated PCR products were transferred to Hybond (Amersham, Arlington Heights, IL), which was then hybridized with a random-primer-labeled probe, washed, and exposed to x-ray film. Exposure time for the blot hybridized with the hCG exon 2 probe was overnight at 23°C. The blot hybridized with the murine CG (mCG) exon 4 probe was exposed for 5 minutes at 23°C.
RNA analysis by S1 protection.
Portions of spleens were homogenized and total cellular RNA was prepared as previously described.37 End-labeled probes for mCG and m 2-microglobulin were prepared and used in S1 nuclease protection assays as described.34 The murine -actin probe was labeled at a Bgl II site in the predicted exon 2; correctly spliced mRNA protects a 135-nt fragment. The hCG-PML-RAR probe was labeled at an Avr II site in the PML portion of the transgene. Correctly spliced human PML mRNA protects a probe fragment of 275 nt from S1 digestion, whereas correctly initiated hCG-PML-RAR mRNA protects a probe fragment of 320 nt.
Assays for hematopoietic colony formation.
Single-cell suspensions of isolated spleens were prepared by homogenization. Nucleated cells (1 × 105) were dispersed in Methocult 3430 complete media (Stem Cell Technologies, Inc, Vancouver, British Columbia, Canada) and plated in quadruplicate. Total colony numbers were quantified after 7 days of growth at 37°C in a humidified incubator with 5% CO2 .
Morphologic and histochemical analyses.
Peripheral blood smears or bone marrow cells prepared as previously described35 were stained with modified Wright's Giemsa (Sigma, St Louis, MO). Six-micron-thick sections of a frozen spleen from a nontransgenic or a transgenic mouse were histochemically stained with the leukocyte peroxidase (myeloperoxidase) kit according to manufacturer's instructions (Sigma).
Intact spleens and livers from either nontransgenic or transgenic mice were isolated, fixed in 10% buffered formalin (Baxter Diagnostics, Deerfield, IL), and subsequently embedded in paraffin. Six-micron-thick sections of these organs were then deparaffinized and stained with hematoxylin and eosin.
Kaplan-Meyer analysis.
Total numbers of nontransgenic or transgenic mice from founder lines 83, 135, and 137 that had postmortem pathologic evidence of myeloid leukemia (defined as massive splenomegaly, leukocytosis, organ infiltration with immature myeloid cells, and clinical illness) were recorded. A Kaplin-Meyer plot was generated using Sigma Plot 3.0 for Windows software (Jandel Scientific, San Rafael, CA).
Tumor formation in SCID mice.
A total of 4 or 5 × 107 splenocytes isolated from transgenic mice with the leukemic phenotype (or from nontransgenic, wild-type littermates) were injected into C3H SCID mice intraperitoneally. These mice were then closely monitored for signs of illness, which occurred at 5 to 6 weeks postinjection in recipients of leukemic splenocytes. At this time, necropsies were performed. Abnormal tissues were processed for histopathologic analysis as described above. Recipients of wild-type splenocytes, although showing no signs of illness, were killed and analyzed in parallel.
ATRA treatment of splenocytes.
Total splenocytes were cultured in RPMI 1640 + 20% fetal calf serum (FCS) + 10 µ/mL penicillin G and 10 µg/mL streptomycin sulfate with or without 1 µmol/L ATRA (Sigma) for 48 hours. At 0, 24, and 48 hours, approximately 2 × 107 cells were harvested. Total cellular RNA was prepared as described37; end-labeled probes were prepared and S1 nuclease protection assays were performed as previously described.34
| |
RESULTS |
Production of transgenic mice expressing PML-RAR in early myeloid cells.
We constructed a transgene containing a PML-RAR cDNA under the control of sequences that regulate the promyelocyte-specific expression of the hCG gene. As mentioned above, these sequences are capable of directing the expression of hCG to the early myeloid cells of transgenic mice.35 The PML-RAR cDNA was subcloned into the 5' untranslated region of the 6-kb hCG genomic fragment (Fig 1A). Expression of the PML-RAR cDNA cassette used in this construct was previously shown to produce phenotypic features of APML blasts when expressed in U937 cells.11 During the construction of this transgene, the initiator ATG of the hCG gene was mutated to TTG to prevent initiation of hCG protein translation. Eight stable founder lines of mice were generated, containing 1 to 15 copies of the hCG-PML-RAR transgene.
View larger version (9K):
[in this window]
[in a new window]
View larger version (25K):
[in this window]
[in a new window]
| Fig 1.
(A) Diagram of the hCG-PML-RAR transgene. Transcription begins at the arrow, the transcriptional start site of the hCG gene. The hCG sequences extend upstream approximately 2.4 kb from the start site. The solid black boxes represent the five exons of the hCG gene; the polyadenylation signal is provided by the hCG gene. Sizes of DNA fragments used in constructing the transgene are denoted below the diagram. (B) RT-PCR analysis of bone marrow RNA. The diagram illustrates the portion of the transgene-specific mRNA that is amplified. The sequences of the forward and reverse primers are also shown. PCR products that hybridize to an hCG exon 2-specific probe shown in the upper autoradiogram indicate the founder lines that express the transgene. In the lower autoradiogram, RNA quality is controlled using primers specific for endogenous mCG exon 4 and a probe specific for detecting these sequences. The RNA source and transgene status is indicated above each lane (founder line/transgene copy number: 67/5, 71/1, 72/15, 83/2, 126/1, 135/4, 137/1, 148/1).
|
|
To identify the founder lines expressing the hCG-PML-RAR transgene, total cellular RNA purified from the bone marrow cells of F1 progeny from each founder line was analyzed by RT-PCR followed by Southern blotting (Fig 1B). The primers used in the PCR amplification were designed based on the sequences at the exon junctions of the correctly processed transgene mRNA to eliminate the amplification of unspliced RNA or contaminating DNA in the reaction mix (see diagram, Fig 1B). The blot was hybridized with a probe specific for the amplified product, which included sequences from correctly spliced hCG exon 2 of the chimeric transgene mRNA; we expected this portion of the transgene to be transcribed and spliced. RNA isolated from the human U937 myeloid leukemic cell line, which expresses high levels of CG mRNA,33 provides a positive control for this assay (Fig 1B, lane 1). No signal is detected using bone marrow RNA isolated from a nontransgenic animal (Fig 1B, lane 7), confirming that this assay is specific for transgene expression. Measurable levels of transgene expression are detected in six of the eight founder lines (Fig 1B). The hybridizing signal is not due to contaminating DNA, because lines 67 and 126 (Fig 1B, lanes 3 and 9, respectively) are transgene-positive but do not produce hybridizing RT-PCR products. The results from this assay are qualitative and identify transgene-expressing founder lines; however, detection is in the linear range, because most of the hybridizing signals vary in intensity. Transgene-specific transcripts were at the limits of detection by S1 nuclease protection analysis (with a sensitivity of ~5 copies of mRNA/cell), indicating that expression levels are very low (data not shown). Mice generated from these founder lines had normal growth, development, and fertility; however, low-level expression of this transgene was sufficient to alter myeloid development in these mice.
Altered myeloid development in transgene-expressing mice.
Virtually all mice that expressed the transgene were found to have an expansion of myeloid cells in their bone marrows and spleens; this phenotype was not dependent on age, sex, or site of transgene integration (ie, the phenotype was observed in 4 independent founder lines). These nonleukemic mice had nearly normal peripheral blood counts, with the exception of a small, but statistically significant, increase in the percentage of morphologically mature myeloid cells (Fig 2). The bone marrow of these mice was packed with myeloid cells at all stages of maturation (Fig 3 and Fig 4A v B); this defect probably caused the extramedullary hematopoiesis found in the interfollicular zones of the spleens (red pulp) of these mice. The expanded red pulp of transgenic spleens contained a substantial increase in the number of cells staining for the myeloid-specific marker myeloperoxidase (Fig 4C v D). Although the red pulp and size of these spleens was expanded, their follicular architecture was preserved (Fig 4D). The presence of increased numbers of hematopoietic progenitors within the spleens of these mice was confirmed using a methylcellulose colony-forming assay: transgenic spleens yielded 86 ± 111 total colonies/105 total spleen cells versus 7 ± 6 colonies/105 total spleen cells in their wild-type littermates (n = 4). The distribution of myeloid and erythroid colonies and colony size were not different between the wild-type and transgenic mice.
View larger version (23K):
[in this window]
[in a new window]
| Fig 2.
Comparison of peripheral blood counts. Values representing the mean ± SD (indicated by error bars) of total white blood cell counts, hemoglobin content, and total platelet counts are shown for nontransgenic or hCG-PML-RAR transgenic mice with nonleukemic or leukemic phenotypes. Statistically significant differences were observed for the percentage of mature myeloid cells in nontransgenic mice versus hCG-PML-RAR (nonleukemic and leukemic) mice (P < .001), the decrease in hemoglobin for hCG-PML-RAR (leukemic) mice (P < .001), and the decrease in platelet counts for hCG-PML-RAR (leukemic) mice (P < .01).
|
|
View larger version (21K):
[in this window]
[in a new window]
| Fig 3.
Comparison of bone marrow differentials. Differentials of 200 cells were performed by two independent observers. Values represent the mean ± SD (indicated by the error bars). hCG-PML-RAR mice have significant (P < .01) increases in early stage myeloid cells (promyelocytes and myelocytes).
|
|
View larger version (122K):
[in this window]
[in a new window]
| Fig 4.
Phenotype of nonleukemic hCG-PML-RAR transgenic mice. (A) Photograph of nontransgenic bone marrow cells stained with Wright's Giemsa. (B) Photograph of bone marrow cells from a nonleukemic, transgene-expressing mouse from founder line 83, stained with Wright's Giemsa. Note that the marrow of this mouse contains predominantly myeloid cells at all stages of differentiation. (C and D) Photographs of spleen sections from (C) a nontransgenic mouse or (D) a nonleukemic, transgene-expressing mouse after histochemical staining for myeloperoxidase activity. A marked increase in cells staining for MPO activity (black stain) is observed in the transgenic spleen.
|
|
We next wanted to determine whether there was an increase in the fraction of promyelocytes within transgenic spleens, using levels of endogenous mCG mRNA as a specific marker. Because expression of CG is restricted to promyelocytes, increases in the levels of mCG mRNA in the spleens of these mice should reflect an increase in the fraction of promyelocytes. RNA isolated from the spleens of both nontransgenic and transgenic, nonleukemic animals from each of the eight founder lines was analyzed using S1 nuclease protection assays (Fig 5). The murine -actin probe assures that the quality and content of the RNAs are equivalent (Fig 5). PML transcripts from human K562 cell RNA are protected by the PML portion of the transgene-specific probe, showing that this probe can detect basal levels of human PML expression in hematopoietic cells (Fig 5, lane 2). hCG-PML-RAR transgene-specific transcripts are not detectable in any of the spleens using this assay, again reflecting the very low levels of transgene expression. Because there are so few promyelocytes in normal mouse spleens, endogenous mCG transcripts are virtually undetectable (Fig 5, lane 7). However, increased levels of endogenous mCG mRNA are observed in founder lines 83, 72, 148, 137, and 135 (Fig 5, lanes 4, 6, 8, 10, and 11, respectively), suggesting that the spleens of transgene-expressing mice contain an increased percentage of promyelocytes.
View larger version (52K):
[in this window]
[in a new window]
| Fig 5.
S1 nuclease protection analysis of spleen RNAs is isolated from hCG-PML-RAR transgenic mice. Molecular size markers are indicated on the left. The expected positions of probe fragments protected by hCG-PML-RAR, mCG, and m actin mRNAs are indicated by the arrows on the right. Founder line and transgene status for each RNA sample are indicated at the bottom. Increases in endogenous mCG mRNA levels are detected in founder lines 83, 72, 148, 137, and 135 (lanes 4, 6, 8, 10, and 11, respectively).
|
|
Development of acute leukemia after a long latent period.
Several transgenic mice eventually developed a severe leukemic phenotype. As a result, three founder lines (83, 135, and 137) were expanded for a tumor watch. A Kaplan-Meyer plot depicts the frequency of leukemia-free survival of mice from these three transgene-expressing lines (Fig 6). Approximately 30% of the transgenic mice from these founder lines have developed the leukemic phenotype, but many mice greater than 6 months of age are still at risk (Fig 6). These mice generally presented with severe leukocytosis usually associated with anemia and/or thrombocytopenia (Fig 2). Massive splenomegaly was consistently observed in these animals (Fig 7A). In addition, the peripheral blood (Fig 2) and the bone marrow (Figs 3 and 7B) of these mice contained high percentages of immature myeloid cells with large numbers of azurophil granules, suggesting a massive expansion of the promyelocyte pool. However, myeloid cells with more differentiated phenotypes were noted in both the peripheral blood and the bone marrow (Figs 2 and 3). When compared with nontransgenic spleens (Fig 5C), the splenic architecture of the leukemic mice was completely disrupted by massive expansion of immature myeloid cells (Fig 5D). Infiltration of myeloid precursors into other organs was also commonly noted in these mice. Histopathologic analysis of an enlarged liver isolated from a representative affected mouse showed an accumulation of myeloid precursors (Fig 5E v F ). None of the mice presented with a bleeding diathesis and disseminated intravascular coagulation (DIC) was not apparent at autopsy in any of the mice with the leukemic phenotype. However, coagulation parameters were not measured in any of the mice, and mice were generally killed at the first signs of clinical illness.
View larger version (14K):
[in this window]
[in a new window]
| Fig 6.
Kaplan-Meyer plot displaying the probability of leukemia-free survival in mice derived from founder lines 83, 135, and 137.
|
|
View larger version (174K):
[in this window]
[in a new window]
| Fig 7.
Phenotype of leukemic, hCG-PML-RAR transgenic mice. (A) Spleens from a nontransgenic littermate (left) and an hCG-PML-RAR transgenic mouse (no. 135-448) with leukemia (right). (B) Bone marrow cells from a leukemic mouse (no. 137-1106) stained with modified Wright's Giemsa. This marrow from the leukemic mouse consists predominantly of very immature myeloid cells that contain abundant azurophil granules (black arrowheads). (C and D) Spleen sections from a nontransgenic mouse (C) or a transgenic mouse (no. 135-448) (D) with leukemia, stained with hematoxylin and eosin. Note the effacement of follicular structures by the leukemic infiltrate. (E and F ) Liver sections from a nontransgenic mouse (E) or mouse no. 135-448 (F ) stained with hematoxylin and eosin. Note the infiltration of the liver with immature myeloid cells (white arrowheads).
|
|
Expression of the hCG-PML-RAR transgene was routinely detected in leukemic mice. Using the RT-PCR strategy described in Fig 1B, leukemic mouse no. 137-1106 was found to express the transgene in the bone marrow and spleen (data not shown). The bone marrow and splenocytes isolated from leukemic mouse no. 137-399 had levels of transgene expression detectable by S1 nuclease protection; in addition to causing a reduction in the levels of endogenous mCG mRNA, ATRA treatment of no. 137-399 splenocytes induced a simultaneous reduction in transgene expression (data not shown). Transgene expression was also detected in the peripheral blood of leukemic mouse no. 135-448 by S1 nuclease protection (data not shown). Thus, leukemic cells continue to express the transgene.
We next wanted to determine the leukemic potential of the immature myeloid cells in the CG-PML-RAR transgenic mice. Four wild-type, nontransgenic C3H SCID mice were injected intraperitoneally with 5 × 107 splenocytes prepared from a transgenic animal with the leukemic phenotype. Two SCID mice were injected with an equal number of splenocytes isolated from a nontransgenic littermate. After 5 weeks, one of the mice injected with splenocytes from the leukemic animal died and the remaining three mice were visibly ill. Autopsies of these mice showed local intraperitoneal infiltration of leukemic myeloid cells and leukemic infiltrates in the mesenteric lymph nodes, livers, and spleens of these animals (data not shown). Promyelocytes were also observed in the bone marrow and peripheral blood of these SCID mice (data not shown). Mice injected with wild-type splenocytes did not develop any evidence of leukemia. In an independent experiment, splenocytes from a second leukemic mouse generated myeloid neoplasms in five of five evaluable SCID mice within 6 weeks of injection. The ability of these spleen preparations to cause tumors in secondary recipients strongly suggests that at least some of the spleen cells are transformed.
View larger version (28K):
[in this window]
[in a new window]
View larger version (68K):
[in this window]
[in a new window]
| Fig 8.
Immature myeloid cells derived from the spleens of hCG-PML-RAR mice are sensitive to ATRA. (A and B) S1 nuclease protection assays using total RNA purified from total splenocytes cultured in the presence or absence of 1 µmol/L ATRA as indicated. Positions of probe bands protected by correctly spliced endogenous mCG or 2 microglobulin mRNAs are shown. Levels of mCG transcripts from nonleukemic (A) or leukemic (B) mice both declined substantially within 24 hours of ATRA treatment. Splenocytes from the nontransgenic littermates of these mice did not have any detectable mCG mRNA at any point during the course of the experiments, as expected. (C and D) Splenocytes from a leukemic mouse (FL no. 135) expressing the hCG-PML-RAR transgene incubated in the absence (C) or presence (D) of 1 µmol/L ATRA for 48 hours. Large clusters of immature myeloid cells (large arrows in [C]) involute in the presence of ATRA (D, large arrow). A macrophage laden with possible nuclear fragments is invading the apoptotic cell cluster (black arrow head). Several cells with fragmented, apoptotic nuclei are seen in the ATRA-treated culture (small arrows).
|
|
ATRA sensitivity of transgenic promyelocytes.
Because most APML patients enter complete remission when treated with ATRA,19,20,22,23 we assessed the ATRA responsiveness of myeloid precursors from both nonleukemic and leukemic mice. Splenocytes were cultured in the absence or presence of 1 µmol/L ATRA for a period of 48 hours. RNA was purified from these cells after 0, 1, or 2 days and analyzed using S1 nuclease protection assays (Fig 8A and B). A probe specific for murine 2 microglobulin controlled for RNA quality and content in these experiments (Fig 8A and B). The levels of mCG transcripts are initially very high in both nonleukemic (Fig 8A, lane 3) and leukemic splenocytes (Fig 8B, lane 1), reflecting an increase in the percentage of splenic promyelocytes. In response to ATRA, mCG transcripts declined after 1 day and were virtually undetectable after 2 days (Fig 8A and B). Thus, the promyelocytes present in the spleens of these transgenic mice are sensitive to ATRA.
The decline of mCG transcripts induced by ATRA could be explained by at least two mechanisms: first, ATRA may be inducing terminal differentiation of the myeloid precursors,13-16 resulting in a loss of mCG expression as cells mature33,34; alternatively, ATRA may induce apoptosis of promyelocytes, causing a reduction in the fraction of these cells that normally express mCG. Analysis of untreated splenocytes from a leukemic mouse after 2 days showed large clusters of self-adherent myeloid cells with an undifferentiated morphology (Fig 8C, large arrows). ATRA treatment caused virtually all of these clusters to undergo apoptosis and involute (Fig 8D, large arrow); macrophages invading these clusters contained numerous inclusions that probably represent nuclear fragments. These findings were reproduced in four independent experiments. Levels of c-fgr transcripts, which increase during terminal myeloid differentiation,38 did not change with ATRA treatment (data not shown). Similarly, flow cytometric analysis of cultured splenocytes did not detect a significant change in the fraction of cells expressing Gr-1, a murine myeloid antigen that is also induced upon maturation (data not shown).
| |
DISCUSSION |
In this report, we describe the production of transgenic mice containing a chimeric PML-RAR fusion cDNA under the control of sequences that target the expression of this cDNA to promyelocytes. Although levels of transgene expression were low, these mice developed an accumulation of myeloid cells in the marrow, which presumably led to the development of extramedullary hematopoiesis in the spleen. This altered myeloid development increased the susceptibility of these animals to the development of acute myeloid leukemia after a long latent period. This leukemic phenotype could be transferred to SCID mice, suggesting that cells from these transgenic mice are transformed. In vitro, splenic promyelocytes expressing the transgene virtually disappeared after 2 days of incubation with ATRA; these promyelocytes are probably eliminated due to ATRA-induced apoptosis. Our results suggest that the PML-RAR fusion protein plays a direct role in altering the process of myeloid development.
The leukemic phenotype of these transgenic mice has similarities and differences when compared with human patients with APML. Thrombocytopenia and anemia, which are characteristic of APML in humans, were consistently observed in these leukemic mice. Both human APML patients and leukemic mice display low percentages of bone marrow blasts and high percentages of bone marrow promyelocytes. Leukemic cells of human APML patients are sensitive to ATRA both in vitro and in vivo. Likewise, promyelocytes from the spleens of our transgenic mice are sensitive to ATRA in culture. The in vivo ATRA sensitivity of our mice is currently being evaluated. However, the severe leukocytosis and organ infiltration observed in our leukemic mice is not a common characteristic of human APML patients and neither is the full range of myeloid maturation in the bone marrow. These differences suggest that targeted expression of PML-RAR to the early myeloid cells of transgenic mice is not sufficient to fully recapitulate the human APML phenotype.
Two other groups have recently attempted to produce animal models of APML. Altabef et al39 reported that retroviral transfer of PML-RAR can transform hematopoietic progenitors and induce acute leukemias in chickens. The vector used in this system produced a fusion protein, with a portion of the retroviral gag protein fused to the N-terminus of PML-RAR. Bone marrow cells infected in culture exhibited a nuclear staining pattern of the gag-PML-RAR protein similar to that of PML-RAR in APML blasts. When chick embryos were infected with the PML-RAR-containing retrovirus, they developed acute leukemia within 2 weeks of hatching. Early et al40 generated transgenic mice with a PML-RAR cDNA driven by the CD11b promoter. The peripheral blood total leukocyte counts and neutrophil counts of these transgenic mice were indistinguishable from control mice. However, peripheral blood leukocytes from these transgenic mice produced fewer colonies in vitro than control mice, most notably in response to granulocyte-macrophage colony-stimulating factor (GM-CSF ). This defect was extended in vivo by showing that only 48% of transgenic mice recovered from a single sublethal dose of radiation. Lack of survival was associated with leukopenia in the transgenic mice; in addition, ATRA treatment of these irradiated transgenic mice enhanced granulocytic recovery. The results of these studies also show that expression of PML-RAR can alter hematopoiesis.
However, neither of these models recapitulate the APML phenotype observed in humans. The CD11b-PML-RAR transgenic mice were phenotypically normal and did not develop leukemia, even after 2 years of observation.40 In the chicken model, the cells transformed in vitro or in vivo resembled multipotential hematopoietic progenitors, rather than the committed precursors characteristic of the human disease.39 In addition, progenitors were transformed only by gag-PML-RAR fusion proteins that had acquired mutations in two domains of PML; no transformed cells were isolated that contained the unaltered form of PML-RAR.39 These mutations have not yet been detected in patients with APML.39 Furthermore, the transformed chicken progenitors were not sensitive to ATRA, which could be due to the mutations acquired in gag-PML-RAR protein or to differences inherent in the avian system.39
The target cell for transformation in APML is likely to be a committed myeloid progenitor.32 Thus, expression of PML-RAR at an early stage of myeloid development may be crucial for leukemogenesis. The CD11b promoter is activated during the late stages of myeloid development and is capable of directing the expression of reporter genes to other hematopoietic lineages in transgenic mice41,42; this may account for the panleukopenia observed in the irradiated CD11b-PML-RAR transgenic mice. Importantly, expression of PML-RAR in late-stage myeloid cells does not produce leukemia in these mice. Retroviral long terminal repeats (LTRs) were used to drive expression of gag-PML-RAR in transduced chicken bone marrow cells.39 Although uncommitted progenitors are transformed by the mutated gag-PML-RAR proteins, their morphology suggests that they may not be the avian equivalents of the target cells in the human disease. In our model, targeting expression of PML-RAR to promyelocytes via CG regulatory sequences produced mice that had a leukemic phenotype that was similar in many respects to the human disease. Comparison of these models suggests that the stage during myeloid development at which PML-RAR is expressed is critical for producing an APML-like phenotype.
The time period required for the development of acute leukemia among hCG-PML-RAR transgenic mice was highly variable, but disease progression was rapid. The leukemic phenotype could be transferred to SCID recipients, which consistently developed clinical illness and myeloid leukemia in a period of 5 to 6 weeks. These recipients may therefore prove useful for testing potential therapeutic agents. A similar SCID ascites model has recently been developed using the human NB4 cell line,43 which was derived from a patient with APML.
The long latency required for hCG-PML-RAR transgenic mice to develop the leukemic phenotype may reflect the low levels of transgene expression observed in our founder lines. It is possible that increasing expression levels of the transgene may decrease the latency for development of leukemia. We are currently addressing this issue by creating mice homozygous for the hCG-PML-RAR transgene, which doubles the transgene dosage. In addition, we are using knock-in technology to target a single copy of the PML-RAR cDNA to the mCG locus; this approach may yield higher expression levels, because the PML-RAR cDNA will be under control of the endogenous mCG promoter and because integration site effects on transgene expression will be eliminated. Nevertheless, our results prove that even low levels of hCG-PML-RAR transgene expression can have a profound effect on myeloid development.
The long latency associated with the development of leukemia in hCG-PML-RAR transgenic mice suggests that PML-RAR is not sufficient to directly cause acute myeloid leukemia in transgenic mice. Long latencies are also characteristic of many other transgenic mouse models involving the cell-type-specific expression of an oncogene; eg, mice expressing SV40 large T-antigen under the control of the myeloid-specific gp91-phox promoter develop histiocytic malignancies only after 6 to 12 months.44 Similarly, lck-Ttg-1 transgenic mice develop thymic tumors after a latent period of 8 to 12 months.45 Long latencies suggest that secondary genetic events may be required for tumor formation. In any case, the development of the leukemic phenotype in hCG-PML-RAR transgenic mice is entirely transgene dependent.
PML-RAR may indirectly contribute to leukemogenesis by causing an accumulation of promyelocytes in the bone marrows and spleens of hCG-PML-RAR transgenic mice, thus increasing the number of myeloid precursors susceptible to secondary mutations. PML-RAR may influence a normal decision that promyelocytes make, ie, a decision to die versus divide and differentiate (Fig 9). PML-RAR may promote the survival of promyelocytes by somehow inhibiting the death pathway. Interestingly, PML-RAR has been shown to confer resistance to apoptosis in U937 clones under conditions of serum deprivation and also to reduce the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent TF-1 cells11,46; this model is therefore consistent with the results obtained from our hCG-PML-RAR mice.
View larger version (49K):
[in this window]
[in a new window]
| Fig 9.
Proposed model for the role of PML-RAR in altered myeloid development. PML-RAR expression in promyelocytes may block a normal apoptotic pathway, allowing some promyelocytes to survive and accumulate second hits that could lead to the development of acute leukemia.
|
|
The long latency observed in this model may be due to the requirement for a second genetic hit. The t(15,17) translocation results in disruption of single alleles of PML and RAR, which may contribute to the APML phenotype in patients; notably, our hCG-PML-RAR mice have two normal alleles of both PML and RAR. Although RAR has been shown to be involved in ATRA-induced myeloid differentiation, mice deficient in RAR have no apparent defect in myeloid development.47,48 This does not preclude the possibility that PML-RAR may promote leukemogenesis in conjunction with the disruption of one allele of PML, one allele of RAR, or both. In fact, a model whereby the disruption of an allele of PML by the t(15,17) translocation cooperates with expression of PML-RAR to produce APML has been suggested.24 Paggi et al49 have shown that mutations in Rb are more frequently associated with APML than any other form of myeloid leukemia; the Rb status of these leukemic mice has not yet been examined. Finally, it is not known whether the expression of the reciprocal RAR-PML fusion gene (found in 70% to 80% of APML patients) may play a role in the pathogenesis of APML.9,10,50 We have generated transgenic mice expressing a RAR-PML cDNA to address this possibility, and we will produce mice coexpressing RAR-PML and PML-RAR. Clearly, the identification of secondary mutations that promote leukemogenesis in the hCG-PML-RAR mice will shed new light on the mechanisms of transformation that lead to APML.
| |
FOOTNOTES |
Submitted August 29, 1996;
accepted October 23, 1996.
Supported by National Institutes of Health Grant No. CA49712 (to T.J.L.).
Address reprint requests to Timothy J. Ley, MD, Washington University Medical School, Departments of Internal Medicine and Genetics, Division of Bone Marrow Transplantation and Stem Cell Biology, 660 S Euclid, Box 8007, St Louis, MO 63110.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Pam Goda for excellent care of these animals and members of the Ley laboratory for their critical comments. Nancy Reidelberger provided expert assistance with the preparation of this manuscript.
| |
REFERENCES |
1.
Rowley JD,
Golomb HM,
Dougherty C:
15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukemia.
Lancet
1:549,
1977[Medline]
[Order article via Infotrieve]
2. Mitelman F: Catalog of Chromosome Aberations in Cancer (ed 4). New York, NY, Liss, 1991
3.
de The H,
Chomienne C,
Lanotte M,
Degos L,
Dejean A:
The t(15; 17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor gene to a novel transcribed locus.
Nature
347:558,
1990[Medline]
[Order article via Infotrieve]
4.
Kakizuka A,
Miller WH Jr,
Umesono K,
Warrell RP Jr,
Frankel SR,
Murty VVVS,
Dmitrovsky E,
Evans RM:
Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RAR with a novel putative transcription factor, PML.
Cell
66:663,
1991[Medline]
[Order article via Infotrieve]
5.
de The H,
Lavau C,
Marchio A,
Chomienne C,
Degos L,
Dejean A:
The PML-RAR fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.
Cell
66:675,
1991[Medline]
[Order article via Infotrieve]
6.
Pandolfi PP,
Grignani F,
Alcalay M,
Mencarelli A,
Biondi A,
LoCoco F,
Grignan F,
Pelicci PG:
Structure and origin of the acute promyelocytic leukemia myl/RAR cDNA and characterization of its retinoid-binding and transactivation properties.
Oncogene
6:1285,
1991[Medline]
[Order article via Infotrieve]
7.
Goddard AD,
Borrow J,
Freemont PS,
Solomon E:
Characterization of a zinc finger gene disrupted by the t(15; 17) in acute promyelocytic leukemia.
Science
254:1371,
1991[Abstract/Free Full Text]
8.
Kastner P,
Perez A,
Lutz Y,
Rochette-Egly C,
Gaub M-P,
Durand B,
Lanotte M,
Berger R,
Chambon P:
Structure, localization and transcriptional properties of two classes of retinoic acid receptor fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins.
EMBO J
11:629,
1992[Medline]
[Order article via Infotrieve]
9.
Chang K-S,
Stass SA,
Chu D-T,
Deaven LL,
Trujillo JM,
Freireich EJ:
Characterization of a fusion cDNA (RAR/myl) transcribed from the t(15; 17) translocation breakpoint in acute promyelocytic leukemia.
Mol Cell Biol
12:800,
1992[Abstract/Free Full Text]
10.
Alcalay M,
Zangrilli D,
Fagioli M,
Pandolfi PP,
Mencarelli A,
LoCoco F,
Biondi A,
Grignani F,
Pelicci PG:
Expression pattern of the RAR-PML fusion gene in acute promyelocytic leukemia.
Proc Natl Acad Sci USA
89:4840,
1992[Abstract/Free Full Text]
11.
Grignani F,
Ferrucci PF,
Testa U,
Talamo G,
Fagioli M,
Alcalay M,
Mencarelli A,
Grignani F,
Peschle C,
Nicoletti I,
Pelicci PG:
The acute promyelocytic leukemia-specific PML-RAR fusion protein inhibits differentiation and promotes survival of myeloid precursor cells.
Cell
74:423,
1993[Medline]
[Order article via Infotrieve]
12.
Rousselot P,
Hardas B,
Patel A,
Guidez F,
Gaken J,
Castaigne S,
Dejean A,
de The H,
Degos L,
Farzaneh F,
Chomienne C:
The PML-RAR gene product of the t(15; 17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.
Oncogene
9:545,
1994[Medline]
[Order article via Infotrieve]
13.
Collins SJ,
Robertson KA,
Mueller L:
Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-).
Mol Cell Biol
10:2154,
1990[Abstract/Free Full Text]
14.
Tsai S,
Collins SJ:
A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage.
Proc Natl Acad Sci USA
90:7153,
1993[Abstract/Free Full Text]
15.
Onodera M,
Kunisada T,
Nishikawa S,
Sakiyama Y,
Matsumoto S,
Nishikawa S-I:
Overexpression of retinoic acid receptor suppresses myeloid cell differentiation at the promyelocytic stage.
Oncogene
11:1291,
1995[Medline]
[Order article via Infotrieve]
16.
Dawson MI,
Elstner E,
Kizaki M,
Chen DL,
Pakkala S,
Kerner B,
Koeffler HP:
Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway.
Blood
84:446,
1994[Abstract/Free Full Text]
17.
Jansen JH,
Mahfoudi A,
Rambaud S,
Lavau C,
Wahli W,
Dejean A:
Multimeric complexes of the PML-retinoic acid receptor fusion protein in acute promyelocytic leukemia cells and interference with retinoic and peroxisome-proliferator signaling pathways.
Proc Natl Acad Sci USA
92:7401,
1995[Abstract/Free Full Text]
18.
Perez A,
Kastner P,
Sethi S,
Lutz Y,
Reibel C,
Chambon P:
PML-RAR homodimers: Distinct DNA binding properties and heteromeric interactions with RXR.
EMBO J
12:3171,
1993[Medline]
[Order article via Infotrieve]
19.
Meng-er H,
Yu-chen Y,
Shu-rong C,
Jia-Xiang L,
Lin Z,
Long-jun G,
Zhen-yi W:
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
Blood
72:567,
1988[Abstract/Free Full Text]
20.
Castaigne S,
Chomienne C,
Daniel MT,
Ballerini P,
Berger R,
Fenaux P,
Degos L:
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.
Blood
76:1704,
1990[Abstract/Free Full Text]
21.
Chomienne C,
Ballerini P,
Balitrand N,
Daniel MT,
Fenaux P,
Castaigne S,
Degos L:
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure-function relationship.
Blood
76:1710,
1990[Abstract/Free Full Text]
22.
LoCocco F,
Avvisati G,
Diverio D,
Petti MC,
Alcalay M,
Pandolfi PP,
Zangrilli D,
Biondi A,
Rambaldi A,
Moleti ML,
Mandelli F,
Pelicci PG:
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia.
Blood
77:1657,
1991[Abstract/Free Full Text]
23.
Warrell RP Jr,
Frankel SR,
Miller WH,
Scheinberg DA,
Itri LM,
Hittelman WN,
Vyas R,
Andreeff M,
Tafuri A,
Jakubowski A,
Gabrilove J,
Gordon MS,
Dmitrovsky E:
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
N Engl J Med
324:1385,
1991[Abstract]
24.
Mu Z-M,
Chin K-V,
Liu J-H,
Lozano G,
Chang K-S:
PML, a growth suppressor disrupted in acute promyelocytic leukemia.
Mol Cell Biol
14:6858,
1994[Abstract/Free Full Text]
25.
Koken MHM,
Linares-Cruz G,
Quignon F,
Viron A,
Chelbi-Alix MK,
Sobczak-Thepot J,
Juhlin L,
Degos L,
Calvo F,
de The H:
The PML growth-suppressor has an altered expression in human oncogenesis.
Oncogene
10:1315,
1995[Medline]
[Order article via Infotrieve]
26.
Flenghi L,
Fagioli M,
Tomassoni L,
Pileri S,
Pacini R,
Grignani F,
Casini T,
Ferrucci PF,
Martelli MF,
Pelicci PG,
Falini B:
Cellular localization and tissue distribution of PML proteins as defined by a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Preferential expression of PML in post-mitotic cells.
Blood
85:1871,
1995[Abstract/Free Full Text]
27.
Daniel MT,
Koken M,
Romagne O,
Barbey S,
Bazarbachi A,
Stadler M,
Guillemin MC,
Degos L,
Chomienne C,
de The H:
PML protein expression in hematopoietic and acute promyelocytic leukemia cells.
Blood
82:1858,
1993[Abstract/Free Full Text]
28.
Dyck JA,
Maul GG,
Miller WH Jr,
Chen JD,
Kakizuka A,
Evans RM:
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.
Cell
76:333,
1994[Medline]
[Order article via Infotrieve]
29.
Weis K,
Rambaud S,
Lavau C,
Jansen J,
Carvalho T,
Carmo-Fonseca M,
Lamond A,
Dejean A:
Retinoic acid regulates aberrant nuclear localization of PML-RAR in acute promyelocytic leukemia cells.
Cell
76:345,
1994[Medline]
[Order article via Infotrieve]
30.
Koken MHM,
Puvion-Dutilleul F,
Guillemin MC,
Viron A,
Linares-Cruz G,
Stuurman N,
Jong L de,
Szostecki C,
Calvo F,
Chomienne C,
Degos L,
Puvion E,
de The H:
The t(15; 17) translocation alters a nuclear body in a retinoic acid-reversible fashion.
EMBO J
13:1073,
1994[Medline]
[Order article via Infotrieve]
31.
Chang K-S,
Fan Y-H,
Andreeff M,
Liu J,
Mu Z-M:
The PML gene encodes a phosphoprotein associated with the nuclear matrix.
Blood
85:3646,
1995[Abstract/Free Full Text]
32.
Turhan AG,
Lemoine FM,
Debert C,
Bonnet ML,
Baillou C,
Picard F,
Macintyre EA,
Varet B:
Highly purified primitive hematopoietic stem cells are PML-RAR negative and generate nonclonal progenitors in acute promyelocytic leukemia.
Blood
85:2154,
1995[Abstract/Free Full Text]
33.
Hanson RD,
Connolly NL,
Burnett D,
Campbell EJ,
Senior RM,
Ley TJ:
Developmental regulation of the human cathepsin G gene in myelomonocytic cells.
J Biol Chem
265:1524,
1990[Abstract/Free Full Text]
34.
Heusel JW,
Scarpati EM,
Jenkins NA,
Gilbert DJ,
Copeland NG,
Shapiro SD,
Ley TJ:
Molecular cloning, chromosomal location, and tissue-specific expression of the murine cathepsin G gene.
Blood
81:1614,
1993[Abstract/Free Full Text]
35.
Grisolano JL,
Sclar GM,
Ley TJ:
Early myeloid cell-specific expression of the human cathepsin G gene in transgenic mice.
Proc Natl Acad Sci USA
91:8989,
1994[Abstract/Free Full Text]
36.
Hanson RD,
Ley TJ:
Transcriptional activation of the human serine protease gene CSP-B in T-lymphocytes.
Mol Cell Biol
10:5655,
1990[Abstract/Free Full Text]
37.
Chomczynski P,
Sacchi N:
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:156,
1987[Medline]
[Order article via Infotrieve]
38.
Ley TJ,
Connolly NL,
Katamine S,
Cheah SC,
Senior RM,
Robbins KC:
Tissue-specific expression and developmental regulation of the human fgr-proto-oncogene.
Mol Cell Biol
9:92,
1989[Abstract/Free Full Text]
39.
Altabef M,
Garcia M,
Lavau C,
Bae S-C,
Dejean A,
Samarut J:
A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RAR fusion gene transforms hematopoietic progenitors in vitro and induces acute leukemia.
EMBO J
15:2707,
1996[Medline]
[Order article via Infotrieve]
40.
Early E,
Moore MAS,
Kakizuka A,
Nason-Burchenal K,
Martin P,
Evans RM,
Dmitrovsky E:
Transgenic expression of PML-RAR impairs myelopoiesis.
Proc Natl Acad Sci USA
93:7900,
1996[Abstract/Free Full Text]
41.
Dziennis S,
Van Etten RA,
Pahl HL,
Morris DL,
Rothstein TL,
Blosch CM,
Perlmutter RM,
Tenen DG:
The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice.
Blood
85:319,
1995[Abstract/Free Full Text]
42.
Back A,
East K,
Hickstein D:
Leukocyte integrin CD11b promoter directs expression in lymphocytes and granulocytes in transgenic mice.
Blood
85:1017,
1995[Abstract/Free Full Text]
43.
Zhang S-Y,
Zhu J,
Chen G-Q,
Du X-X,
Lu L-J,
Zhang Z,
Zhong H-J,
Chen H-R,
Wang Z-Y,
Berger R,
Lanotte M,
Waxman S,
Chen Z,
Chen S-J:
Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice.
Blood
87:3404,
1996[Abstract/Free Full Text]
44.
Skalnik DG,
Dorfman DM,
Perkins AS,
Jenkins NA,
Copeland NG,
Orkin SH:
Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies.
Proc Natl Acad Sci USA
88:8505,
1991[Abstract/Free Full Text]
45.
McGuire EA,
Rintoul CE,
Sclar GM,
Korsmeyer SJ:
Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma.
Mol Cell Biol
12:4186,
1992[Abstract/Free Full Text]
46.
Rogaia D,
Grignani F,
Nicolleti I,
Pelicci PG:
The acute promyelocytic leukemia-specific PML-RAR fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells.
Leukemia
9:1467,
1995[Medline]
[Order article via Infotrieve]
47.
Li E,
Sucov HM,
Lee K-F,
Evans RM,
Jaenisch R:
Normal development and growth of mice carrying a targeted disruption of the 1 retinoic acid receptor gene.
Proc Natl Acad Sci USA
90:1590,
1993[Abstract/Free Full Text]
48.
Lufkin T,
Lohnes D,
Mark M,
Dierich A,
Gorry P,
Gaub M-P,
LeMeur M,
Chambon P:
High postnatal lethality and testis degeneration in retinoic acid receptor mutant mice.
Proc Natl Acad Sci USA
90:7225,
1993[Abstract/Free Full Text]
49.
Paggi M,
de Fabritiis P,
Bonetto F,
Amadio L,
Santarelli G,
Spadea A,
Gentile FP,
Floridi A,
Felsani A:
The retinoblastoma gene product in acute myeloid leukemia: A possible involvement in promyelocytic leukemia.
Cancer Res
55:4552,
1995[Abstract/Free Full Text]
50.
Lafage-Pochitaloff M,
Alcalay M,
Brunel V,
Longo L,
Sainty D,
Simonetti J,
Birg F,
Pelicci PG:
Acute promyelocytic leukemia cases with nonreciprocal PML-RAR or RAR/PML fusion genes.
Blood
85:1169,
1995[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Nasr, V. Lallemand-Breitenbach, J. Zhu, M.-C. Guillemin, and H. de The
Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure
Clin. Cancer Res.,
October 15, 2009;
15(20):
6321 - 6326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Akagi, L.-Y. Shih, M. Kato, N. Kawamata, G. Yamamoto, M. Sanada, R. Okamoto, C. W. Miller, D.-C. Liang, S. Ogawa, et al.
Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations
Blood,
February 19, 2009;
113(8):
1741 - 1748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Funk, T. J. Maxwell, M. Izumi, D. Edwin, F. Kreisel, T. J. Ley, J. M. Cheverud, and T. A. Graubert
Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice
Blood,
August 15, 2008;
112(4):
1434 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-B. Zhou, J. Zhang, Z.-Y. Wang, S.-J. Chen, and Z. Chen
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy
Phil Trans R Soc B,
June 29, 2007;
362(1482):
959 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Yuan, J. E. Payton, M. S. Holt, D. C. Link, M. A. Watson, J. F. DiPersio, and T. J. Ley
Commonly dysregulated genes in murine APL cells
Blood,
February 1, 2007;
109(3):
961 - 970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Walter, R. E. Ries, J. R. Armstrong, J. S. Park, E. R. Mardis, and T. J. Ley
Expression of a bcr-1 isoform of RAR{alpha}-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2
Blood,
February 1, 2007;
109(3):
1237 - 1240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. P. Ng, J. Howe Fong, D. Sijin Nin, J. L. Hirpara, N. Asou, C.-S. Chen, S. Pervaiz, and M. Khan
Cleavage of misfolded nuclear receptor corepressor confers resistance to unfolded protein response-induced apoptosis.
Cancer Res.,
October 15, 2006;
66(20):
9903 - 9912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Carver and P. P. Pandolfi
Mouse modeling in oncologic preclinical and translational research.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5305 - 5311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. T. Chan, J. L. Kutok, I. R. Williams, S. Cohen, S. Moore, H. Shigematsu, T. J. Ley, K. Akashi, M. M. Le Beau, and D. G. Gilliland
Oncogenic K-ras cooperates with PML-RAR{alpha} to induce an acute promyelocytic leukemia-like disease
Blood,
September 1, 2006;
108(5):
1708 - 1715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Xu, F. Guidez, A. Glasow, D. Chung, K. Petrie, K. Stegmaier, K.-K. Wang, J. Zhang, Y. Jing, A. Zelent, et al.
Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor {alpha} and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression
Cancer Res.,
September 1, 2005;
65(17):
7856 - 7865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Walter, J. S. Park, R. E. Ries, S. K. M. Lau, M. McLellan, S. Jaeger, R. K. Wilson, E. R. Mardis, and T. J. Ley
Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RAR{alpha}
PNAS,
August 30, 2005;
102(35):
12513 - 12518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. T. Porse, D. Bryder, K. Theilgaard-Monch, M. S. Hasemann, K. Anderson, I. Damgaard, S. E. W. Jacobsen, and C. Nerlov
Loss of C/EBP{alpha} cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage
J. Exp. Med.,
July 5, 2005;
202(1):
85 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Lane and T. J. Ley
Neutrophil Elastase Is Important for PML-Retinoic Acid Receptor {alpha} Activities in Early Myeloid Cells
Mol. Cell. Biol.,
January 1, 2005;
25(1):
23 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Walter, J. S. Park, S. K. M. Lau, X. Li, A. A. Lane, R. Nagarajan, W. D. Shannon, and T. J. Ley
Expression Profiling of Murine Acute Promyelocytic Leukemia Cells Reveals Multiple Model-Dependent Progression Signatures
Mol. Cell. Biol.,
December 15, 2004;
24(24):
10882 - 10893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsuzuki, K. Kitajima, T. Nakano, A. Glasow, A. Zelent, and T. Enver
Cross Talk between Retinoic Acid Signaling and Transcription Factor GATA-2
Mol. Cell. Biol.,
August 1, 2004;
24(15):
6824 - 6836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zheng, T. Beissert, N. Kukoc-Zivojnov, E. Puccetti, J. Altschmied, C. Strolz, S. Boehrer, H. Gul, O. Schneider, O. G. Ottmann, et al.
{gamma}-Catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells
Blood,
May 1, 2004;
103(9):
3535 - 3543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Muller-Tidow, B. Steffen, T. Cauvet, L. Tickenbrock, P. Ji, S. Diederichs, B. Sargin, G. Kohler, M. Stelljes, E. Puccetti, et al.
Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells
Mol. Cell. Biol.,
April 1, 2004;
24(7):
2890 - 2904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Gilliland, C. T. Jordan, and C. A. Felix
The Molecular Basis of Leukemia
Hematology,
January 1, 2004;
2004(1):
80 - 97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Hansen, D. Brown, V. Virador, T. Tanaka, F. Andreola, K. Strain, B. Dancheck, R. Riley, J. M. Arbeit, L. M. De Luca, et al.
A PMLRARA Transgene Results in a Retinoid-deficient Phenotype Associated with Enhanced Susceptibility to Skin Tumorigenesis
Cancer Res.,
September 1, 2003;
63(17):
5257 - 5265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Westervelt, A. A. Lane, J. L. Pollock, K. Oldfather, M. S. Holt, D. B. Zimonjic, N. C. Popescu, J. F. DiPersio, and T. J. Ley
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RAR{alpha} expression
Blood,
September 1, 2003;
102(5):
1857 - 1865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Phan, D. B. Shultz, B.-T. H. Truong, T. J. Blake, A. L. Brown, T. J. Gonda, M. M. Le Beau, and S. C. Kogan
Cooperation of Cytokine Signaling with Chimeric Transcription Factors in Leukemogenesis: PML-Retinoic Acid Receptor Alpha Blocks Growth Factor-Mediated Differentiation
Mol. Cell. Biol.,
July 1, 2003;
23(13):
4573 - 4585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. McHale, J. L. Wiemels, L. Zhang, X. Ma, P. A. Buffler, J. Feusner, K. Matthay, G. Dahl, and M. T. Smith
Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16)
Blood,
June 1, 2003;
101(11):
4640 - 4641.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sohal, V. T. Phan, P. V. Chan, E. M. Davis, B. Patel, L. M. Kelly, T. J. Abrams, A. M. O'Farrell, D. G. Gilliland, M. M. Le Beau, et al.
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
Blood,
April 15, 2003;
101(8):
3188 - 3197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Puccetti, D. Obradovic, T. Beissert, A. Bianchini, B. Washburn, F. Chiaradonna, S. Boehrer, D. Hoelzer, O. G. Ottmann, P. G. Pelicci, et al.
AML-associated Translocation Products Block Vitamin D3-induced Differentiation by Sequestering the Vitamin D3 Receptor
Cancer Res.,
December 1, 2002;
62(23):
7050 - 7058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Minucci, S. Monestiroli, S. Giavara, S. Ronzoni, F. Marchesi, A. Insinga, D. Diverio, P. Gasparini, M. Capillo, E. Colombo, et al.
PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors
Blood,
September 26, 2002;
100(8):
2989 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Westervelt, J. L. Pollock, K. M. Oldfather, M. J. Walter, M. K. Ma, A. Williams, J. F. DiPersio, and T. J. Ley
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia
PNAS,
July 9, 2002;
99(14):
9468 - 9473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Kelly, J. L. Kutok, I. R. Williams, C. L. Boulton, S. M. Amaral, D. P. Curley, T. J. Ley, and D. G. Gilliland
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
PNAS,
June 11, 2002;
99(12):
8283 - 8288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Dash, I. R. Williams, J. L. Kutok, M. H. Tomasson, E. Anastasiadou, K. Lindahl, S. Li, R. A. Van Etten, J. Borrow, D. Housman, et al.
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
PNAS,
May 28, 2002;
99(11):
7622 - 7627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Le Beau, S. Bitts, E. M. Davis, and S. C. Kogan
Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia
Blood,
April 15, 2002;
99(8):
2985 - 2991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. K. Andersen, D. H. Christiansen, and C. Nerlov
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
Blood,
March 15, 2002;
99(6):
1909 - 1912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
Blood,
January 1, 2002;
99(1):
310 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yuan, L. Zhou, T. Miyamoto, H. Iwasaki, N. Harakawa, C. J. Hetherington, S. A. Burel, E. Lagasse, I. L. Weissman, K. Akashi, et al.
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations
PNAS,
August 28, 2001;
98(18):
10398 - 10403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Sweetser, C.-S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, et al.
Loss of heterozygosity in childhood de novo acute myelogenous leukemia
Blood,
August 15, 2001;
98(4):
1188 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Kini, L. C. Peterson, M. S. Tallman, and M. W. Lingen
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid
Blood,
June 15, 2001;
97(12):
3919 - 3924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Liao, X. Y. Wang, H. Q. Wei, S. Q. Li, T. Merghoub, P. P. Pandolfi, and D. J. Wolgemuth
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1
PNAS,
May 24, 2001;
(2001)
121540098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Pandolfi
Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia
Hum. Mol. Genet.,
April 1, 2001;
10(7):
769 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-S. Wu, S. Vallian, E. Seto, W.-M. Yang, D. Edmondson, S. Roth, and K.-S. Chang
The Growth Suppressor PML Represses Transcription by Functionally and Physically Interacting with Histone Deacetylases
Mol. Cell. Biol.,
April 1, 2001;
21(7):
2259 - 2268.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. C. Kogan, D. E. Brown, D. B. Shultz, B.-T. H. Truong, V. Lallemand-Breitenbach, M.-C. Guillemin, E. Lagasse, I. L. Weissman, and J. M. Bishop
Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor {alpha} Chimeric Protein (Pmlrar{alpha}) to Block Neutrophil Differentiation and Initiate Acute Leukemia
J. Exp. Med.,
February 19, 2001;
193(4):
531 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Largaespada
Haploinsufficiency for Tumor Suppression: The Hazards of Being Single and Living a Long Time
J. Exp. Med.,
February 19, 2001;
193(4):
f15 - f18.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hauksdóttir and M. L. Privalsky
DNA Recognition by the Aberrant Retinoic Acid Receptors Implicated in Human Acute Promyelocytic Leukemia
Cell Growth Differ.,
February 1, 2001;
12(2):
85 - 98.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. F. Ferrara, F. Fazi, A. Bianchini, F. Padula, V. Gelmetti, S. Minucci, M. Mancini, P. G. Pelicci, F. L. Coco, and C. Nervi
Histone Deacetylase-targeted Treatment Restores Retinoic Acid Signaling and Differentiation in Acute Myeloid Leukemia
Cancer Res.,
January 1, 2001;
61(1):
2 - 7.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Muller, R. Yang, D. J. Park, H. Serve, W. E. Berdel, and H. P. Koeffler
The aberrant fusion proteins PML-RARalpha and PLZF-RARalpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia
Blood,
December 1, 2000;
96(12):
3894 - 3899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Zimonjic, J. L. Pollock, P. Westervelt, N. C. Popescu, and T. J. Ley
Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
PNAS,
November 21, 2000;
97(24):
13306 - 13311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Heydemann, S. Warming, C. Clendenin, K. Sigrist, J. P. Hjorth, and M. C. Simon
A minimal c-fes cassette directs myeloid-specific expression in transgenic mice
Blood,
November 1, 2000;
96(9):
3040 - 3048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Rhoades, C. J. Hetherington, N. Harakawa, D. A. Yergeau, L. Zhou, L.-Q. Liu, M.-T. Little, D. G. Tenen, and D.-E. Zhang
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
Blood,
September 15, 2000;
96(6):
2108 - 2115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Shao, A. Rosenauer, K. Mann, C.-P. B. Chang, C. Rachez, L. P. Freedman, and W. H. Miller Jr
Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells
Blood,
September 15, 2000;
96(6):
2233 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grignani, M. Valtieri, M. Gabbianelli, V. Gelmetti, R. Botta, L. Luchetti, B. Masella, O. Morsilli, E. Pelosi, P. Samoggia, et al.
PML/RARalpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype
Blood,
August 15, 2000;
96(4):
1531 - 1537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Hansen, C. C. Sigman, F. Andreola, S. A. Ross, G. J. Kelloff, and L. M. De Luca
Retinoids in chemoprevention and differentiation therapy
Carcinogenesis,
July 1, 2000;
21(7):
1271 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Redner, J. D. Chen, E. A. Rush, H. Li, and S. L. Pollock
The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties
Blood,
April 15, 2000;
95(8):
2683 - 2690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Li, C. Leo, J. Zhu, X. Wu, J. O'Neil, E.-J. Park, and J. D. Chen
Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML
Mol. Cell. Biol.,
March 1, 2000;
20(5):
1784 - 1796.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. C. Kogan, S.-h. Hong, D. B. Shultz, M. L. Privalsky, and J. M. Bishop
Leukemia initiated by PMLRARalpha : the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable
Blood,
March 1, 2000;
95(5):
1541 - 1550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Pollock, P. Westervelt, A. K. Kurichety, P. G. Pelicci, J. L. Grisolano, and T. J. Ley
A bcr-3 isoform of RARalpha -PML potentiates the development of PML-RARalpha -driven acute promyelocytic leukemia
PNAS,
December 21, 1999;
96(26):
15103 - 15108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Du, R. L. Redner, M. P. Cooke, and C. Lavau
Overexpression of Wild-Type Retinoic Acid Receptor alpha (RARalpha ) Recapitulates Retinoic Acid-Sensitive Transformation of Primary Myeloid Progenitors by Acute Promyelocytic Leukemia RARalpha -Fusion Genes
Blood,
July 15, 1999;
94(2):
793 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sternsdorf, E. Puccetti, K. Jensen, D. Hoelzer, H. Will, O. G. Ottmann, and M. Ruthardt
PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor alpha Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia
Mol. Cell. Biol.,
July 1, 1999;
19(7):
5170 - 5178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Coco, D. Diverio, B. Falini, A. Biondi, C. Nervi, and P. G. Pelicci
Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
Blood,
July 1, 1999;
94(1):
12 - 22.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-X. Cheng, X.-H. Zhu, X.-Q. Men, L. Wang, Q.-H. Huang, X. L. Jin, S.-M. Xiong, J. Zhu, W.-M. Guo, J.-Q. Chen, et al.
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha
PNAS,
May 25, 1999;
96(11):
6318 - 6323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood,
May 15, 1999;
93(10):
3167 - 3215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Westervelt and T. J. Ley
Seed Versus Soil: The Importance of the Target Cell for Transgenic Models of Human Leukemias
Blood,
April 1, 1999;
93(7):
2143 - 2148.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fanelli, S. Minucci, V. Gelmetti, C. Nervi, C. Gambacorti-Passerini, and P. G. Pelicci
Constitutive Degradation of PML/RARalpha Through the Proteasome Pathway Mediates Retinoic Acid Resistance
Blood,
March 1, 1999;
93(5):
1477 - 1481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vallian, K.-V. Chin, and K.-S. Chang
The Promyelocytic Leukemia Protein Interacts with Sp1 and Inhibits Its Transactivation of the Epidermal Growth Factor Receptor Promoter
Mol. Cell. Biol.,
December 1, 1998;
18(12):
7147 - 7156.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Muller, W. H. Miller Jr, and A. Dejean
Trivalent Antimonials Induce Degradation of the PML-RARalpha Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells
Blood,
December 1, 1998;
92(11):
4308 - 4316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nervi, F. F. Ferrara, M. Fanelli, M. R. Rippo, B. Tomassini, P. F. Ferrucci, M. Ruthardt, V. Gelmetti, C. Gambacorti-Passerini, D. Diverio, et al.
Caspases Mediate Retinoic Acid-Induced Degradation of the Acute Promyelocytic Leukemia PML/RARalpha Fusion Protein
Blood,
October 1, 1998;
92(7):
2244 - 2251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gianni, M. H.M. Koken, M. K. Chelbi-Alix, G. Benoit, M. Lanotte, Z. Chen, and H. de The
Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells
Blood,
June 1, 1998;
91(11):
4300 - 4310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Slack and M. Yu
Constitutive Expression of the Promyelocytic Leukemia-Associated Oncogene PML-RARalpha in TF1 Cells: Isoform-Specific and Retinoic Acid-Dependent Effects on Growth, bcl-2 Expression, and Apoptosis
Blood,
May 1, 1998;
91(9):
3347 - 3356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alcalay, L. Tomassoni, E. Colombo, S. Stoldt, F. Grignani, M. Fagioli, L. Szekely, K. Helin, and P. G. Pelicci
The Promyelocytic Leukemia Gene Product (PML) Forms Stable Complexes with the Retinoblastoma Protein
Mol. Cell. Biol.,
February 1, 1998;
18(2):
1084 - 1093.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R.J. LIN, H.-Y. KAO, P. ORDENTLICH, and R.M. EVANS
The Transcriptional Basis of Steroid Physiology
Cold Spring Harb Symp Quant Biol,
January 1, 1998;
63(0):
577 - 586.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Sternsdorf, K. Jensen, and H. Will
Evidence for Covalent Modification of the Nuclear Dot-associated Proteins PML and Sp100 by PIC1/SUMO-1
J. Cell Biol.,
December 29, 1997;
139(7):
1621 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade, P. Gorman, E. Duprez, K. Howe, S. Langabeer, F. Oliver, H. Walker, D. Culligan, J. Waters, M. Pomfret, et al.
Characterization of Cryptic Rearrangements and Variant Translocations in Acute Promyelocytic Leukemia
Blood,
December 15, 1997;
90(12):
4876 - 4885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Ferrucci, F. Grignani, M. Pearson, M. Fagioli, I. Nicoletti, and P. G. Pelicci
Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein
PNAS,
September 30, 1997;
94(20):
10901 - 10906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Hong, G. David, C.-W. Wong, A. Dejean, and M. L. Privalsky
SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha ) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia
PNAS,
August 19, 1997;
94(17):
9028 - 9033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Tenen, R. Hromas, J. D. Licht, and D.-E. Zhang
Transcription Factors, Normal Myeloid Development, and Leukemia
Blood,
July 15, 1997;
90(2):
489 - 519.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Brown, S. Kogan, E. Lagasse, I. Weissman, M. Alcalay, P. G. Pelicci, S. Atwater, and J. M. Bishop
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia
PNAS,
March 18, 1997;
94(6):
2551 - 2556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Liao, X. Y. Wang, H. Q. Wei, S. Q. Li, T. Merghoub, P. P. Pandolfi, and D. J. Wolgemuth
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1
PNAS,
June 5, 2001;
98(12):
6853 - 6858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract